Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients.

ABSTRACT: Glioblastoma is a dreadful disease with very poor prognosis, median overall survival being <2 years despite standard-of-care treatment. This has led to the development of alternative strategies, among which immunotherapy is being actively tested. In particular, many clinical trials of therapeutic vaccination using peptides or tumor cells are ongoing. A major issue in implementing therapeutic vaccines in patients with high-grade glioma is that immune responses have to be elicited in the context of immunosuppressive treatments. Indeed, radiotherapy, chemotherapy, and steroids, which are part of the standard of care for patients with glioblastoma, are known to deplete leukocytes. Whether lymphopenia is beneficial or detrimental to elicitation of efficient immune responses is still debated. He

SUBMITTER: Dutoit V 

PROVIDER: S-EPMC7034105 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature